The latest announcement is out from Avalon GloboCare ( (ALBT) ).
On April 10, 2025, Avalon GloboCare Corp. announced the issuance of a patent and Certificate of Invention for its CAR-T and CAR-NK cell technology by the China National Intellectual Property Administration. This patent, co-developed with Arbele Limited, enhances Avalon’s intellectual property portfolio and strengthens its position in the global market for cell-based immunotherapy. The patent covers innovative technology aimed at improving the efficacy and survival of CAR-T and CAR-NK cells, including a bispecific anti-CD19xCD22 CAR design and localized cytokine induction mechanism. This development marks a significant milestone in Avalon’s global intellectual property strategy, providing 20 years of protection and reinforcing its commitment to pioneering cancer treatments.
More about Avalon GloboCare
Avalon GloboCare Corp. is a commercial-stage company focused on developing and delivering precision diagnostic consumer products and advancing intellectual property in cellular therapy. The company markets the KetoAir™ breathalyzer device and plans to expand its diagnostic applications, while also owning and operating commercial real estate.
YTD Price Performance: 16.62%
Average Trading Volume: 73,305
Technical Sentiment Signal: Strong Buy
Current Market Cap: $6.61M
For detailed information about ALBT stock, go to TipRanks’ Stock Analysis page.